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In this two-way crossover, double-blind, double-dummy study, 17 adults with
mild-to-moderate COPD were randomized to receive either formoterol 24 mg
(2 12 mg via Aerolizers), or salbutamol 600 mg (6 100 mg via metered-dose
inhaler), and the appropriate double-dummy q.i.d. at 4-h intervals for 3 consecutive
days (total daily dose: 96 and 2400 mg, respectively). After a 4–7-day washout
period, patients were switched to the other treatment.
Treatment with high-dose formoterol and salbutamol was equally well tolerated, with
no reports of serious adverse events. Both agents were associated with decreased plasma
potassium (mean minimum values: 3.4 and 3.3mmol/l for formoterol and salbutamol,
respectively; P ¼ 0.914), increased serum glucose (mean maximum values: 9.0 and
8.7mmol/l, respectively; P ¼ 0.373), and small increases in mean QTc interval (mean
maximum 439ms with both treatments; P ¼ 0.813). No clinically relevant between-
treatment differences in adverse events or laboratory values occurred. Both drugs
improved lung function (mean maximum forced expiratory volume in 1 s [FEV1] 2.6 l with
both treatments; P ¼ 0.624), with the improvement being significantly greater with
formoterol than with salbutamol on all 3 days of treatment (mean area under the curve
[AUC](0–24h) of FEV1 formoterol vs. salbutamol on days 1–3, all Po0.05).Elsevier Ltd. All rights reserved.
778 4377; fax: +1 973 781 8865.
artis.com (A. Horowitz).
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Safety of high-dose formoterol and salbutamol in COPD 667High-dose formoterol via Aerolizers (up to 96mg/day) has a comparable tolerability
profile to that of salbutamol in patients with mild-to-moderate COPD.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
debilitating disease of the airways and lung inter-
stitial tissue, which is characterized by symptoms of
chronic cough, sputum production and dyspnoea, and
for which bronchodilators represent the cornerstone
of symptom-driven therapeutic management.1 Short-
acting b2-adrenoceptor agonists, such as salbutamol,
are widely used for providing rapid relief from COPD
symptoms, whereas the long-acting b2-adrenoceptor
agonists, formoterol and salmeterol, are recom-
mended for maintenance therapy.1–4 Maintenance
use of formoterol is known to improve lung function
and reduce COPD symptoms.2–4
In addition to its long duration of action (412 h),
formoterol has a rapid onset of action (1–3min
post-dose).5,6 In practice, patients with COPD may
therefore use formoterol for on-demand symptom
relief. However, because these patients may
experience several consecutive days of worsening
symptoms, the likelihood of high cumulative doses
of any bronchodilator over time may be a concern.
The present controlled clinical study was designed
to simulate this scenario.
This study evaluated the safety and tolerability
profile of high-dose formoterol (96 mg daily) com-
pared with therapeutically equivalent doses of
salbutamol (2400 mg daily) administered over 3
consecutive days in patients with stable COPD.
The maximum approved dose of formoterol in some
countries is 24 mg b.i.d. (total daily dose of 48 mg)
for maintenance treatment of COPD. In compar-
ison, the American Thoracic Society recommends
salbutamol via MDI be administered at a dose not to
exceed 8–12 puffs every 24 h (i.e. 1200 mg) for
the treatment of mild intermittent symptoms.7
The doses selected for this study are twice the
maximum total daily dose recommended for the
treatment of mild intermittent symptoms in COPD
(2 1200 mg salbutamol vs. 2 48 mg formoterol).
The primary aim was to confirm an acceptable
safety margin for formoterol above the highest dose
most likely to be administered during an exacerbation.Materials and methods
This randomized, double-blind, two-way crossover
study enrolled 17 adult patients (aged 45–64 [mean
54] years; 17.6% female) with a confirmed diagnosisof COPD.7 The study was conducted at Parexel
(Berlin, Germany) and CentreCap (Montpellier,
France). All patients had prebronchodilator forced
expiratory volume in 1 s (FEV1) of X750ml and
35–75% predicted. All patients had a history of
smoking with the majority (16/17 patients rando-
mized) being current smokers (20–72 pack-years).
Exclusion criteria: concomitant asthma or a
history of childhood asthma; respiratory tract
infection, hospitalization or emergency room treat-
ment for an acute COPD exacerbation within the
previous month; need for long-term oxygen ther-
apy; history of clinically relevant electrocardio-
gram (ECG) abnormalities or a family history of
prolonged QT interval syndrome; history of unto-
ward reactions to b2-adrenoceptor agonists; and/or
current diagnosis or history of clinically relevant
conditions that might compromise the patient’s
safety or study evaluations. Additionally, patients
who were immunocompromised and/or women who
were not surgically sterile, postmenopausal, or
using an adequate method of birth control were
excluded. Written informed consent was provided
by all enrolled patients. The study was conducted
in accordance with the latest revisions to the
Declaration of Helsinki and local ethical committee
approval at the two participating centres.
After a run-in period of 4 weeks (during which
patients demonstrated correct use of study inhaler
devices) and completion of baseline assessments,
patients received either formoterol 24 mg (Fora-
dils) via Aerolizers or salbutamol 600 mg (Vento-
lins) via metered-dose inhaler four times daily
(q.i.d.) for 3 consecutive days (total daily dose: 96
and 2400 mg, respectively) in the first treatment
period, according to the treatment sequence group
that they were randomly assigned to. Treatment
was administered at 4-h intervals on each day.
After a 4–7-day washout period, patients received
the opposite comparator during the second treat-
ment period. All patients remained at the study
centre on each treatment day and treatment
adherence was assured by study personnel. Blinding
was maintained by the use of double-dummy
placebo inhalers. Treatment with medication other
than the study drugs was not allowed, except for
the treatment of adverse events (e.g. paracetamol
for headache). Concomitant treatment with in-
haled or intranasal corticosteroids was permitted
provided that such therapy had neither commenced
nor been subject to any change in daily dose or
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Theophyllines, oral or inhaled anticholinergics and
oral or inhaled b2-adrenoceptor agonists were also
allowed with a pre-dose washout period between 6
and 72 h specified for each drug. Limited rescue
salbutamol was also allowed. Patients were re-
quired to refrain from strenuous physical exercise
or consumption of alcohol or xanthine-containing
foods and beverages during the study.Evaluation of safety
The following safety assessments were completed
following each dose of study medication: 12-lead
ECG recordings; vital signs (supine blood pressure
and radial pulse rate); and adverse event monitor-
ing. ECG recordings and vital sign measurements
were completed at 15min pre-dose, at 1 and 2 h
post-dose and at 1, 2 and 4 h after the final dose on
each treatment day (blood pressure was not
recorded at the 1-h post-dose assessment). In
addition, safety assessments corresponding to the
known systemic effects of b2-adrenoceptor agonists
(plasma potassium, blood glucose and QT interval
changes [corrected using Bazett’s formula, QT
interval/ORR interval] were performed). Blood
samples were collected at 15min pre-dose and at
1, 2 and 3 h after each dose (a further blood sample
was collected at 4 h after the final daily dose) for
plasma potassium and blood glucose levels. Clinical
laboratory assessments (haematology, serum chem-
istry, and urinalysis) were performed at screening,
baseline, and end of study. Additionally, FEV1 (best
of 3 manoeuvres) was evaluated at 15min pre-dose
and at 2 h post-dose.Statistical analysis
The main objective of the study was to gather
safety and tolerability information during multiple,
high-dose administration of formoterol in patients
with COPD. Sample size was based on practical
considerations rather than a formal sample size
calculation. Although only 16 patients were
planned, an additional patient was randomized.
The following variables were included in the
statistical analysis: plasma potassium (area under
the curve [AUC] and minimum), blood glucose (AUC
and maximum), QTc interval (AUC and maximum);
and FEV1 (AUC and maximum). AUC was calculated
using the linear trapezoidal method for the inter-
vals 0–24, 24–48, 48–72 and 0–72 h post-dose.
Minimum and maximum values were defined as
the lowest and highest values observed during the
two treatment periods. All variables were log-transformed and analyzed using a linear mixed-
effect model that included treatment, period and
sequence as fixed factors, subject-within-sequence
as a random factor and log-transformed baseline
value as covariate.
Randomization and allocation
Randomization was performed by Novartis Drug
Supply Management using a validated automated
system that was approved by Novartis Biostatistics
Quality Assurance and thereafter locked. Patients
were randomized to one of two treatment se-
quences. At each treatment period, patients were
given the corresponding period pack from their
‘patient pack’.Results
Demographics and baseline characteristics of the
study population are shown in Table 1. Overall, 17
patients were randomized and 16 patients com-
pleted the study with no major protocol violations;
one male subject was withdrawn prior to the
second treatment period due to a positive drug
test. Salbutamol rescue medication was not re-
quired by any patient during the study period. Two
patients took concomitant paracetamol for head-
ache, one patient took lacitol for constipation and
another patient took paracetamol and metoclopra-
mide for gastroenteritis, all of which occurred
during formoterol treatment.
Adverse events
Treatment with high-dose formoterol and salbuta-
mol was well tolerated. Four patients reported
adverse events following formoterol treatment
(headache, n ¼ 2; viral gastroenteritis, n ¼ 1;
constipation and diarrhoea, n ¼ 1) and 2 patients
reported adverse events following salbutamol
(head pressure, n ¼ 1; tremor, n ¼ 1). One further
patient experienced headache during both treat-
ment periods, which was accompanied by nausea
and neck stiffness during the administration of
formoterol. All adverse events were of mild
intensity, except for one incidence of moderate
non-drug-related viral gastroenteritis.
Changes in plasma potassium and blood
glucose
Both formoterol and salbutamol were associated
with moderate decreases from pre-dose values (day
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Figure 1 Mean (SD) AUC values during 0–72 h time period
and each separate 24-h period for (a) plasma potassium,
(b) plasma glucose and (c) QTc interval in patients with
mild-to-moderate COPD receiving formoterol 24 mg or
salbutamol 600 mg q.i.d.; *Po0.05 vs. salbutamol.
Table 1 Summary of demographic and baseline characteristics.
Formoterol n ¼ 17 Salbutamol n ¼ 16
Males, n 14 13
Mean age, years (range) 53.8 (45–64) 54.1 (45–64)
Mean bodyweight, kg (range) 73.8 (59.0–99.7) 74.4 (59.0–99.7)
Mean duration of COPD before study, years 6.3 6.5
Mean FEV1, l (range)
y 1.84 (1.14–2.84) 1.80 (1.03–2.80)
Mean serum potassium, mmol/l (range)y 4.74 (3.94–5.26) 4.53 (3.50–5.30)
Mean blood glucose, mmol/l (range)y 5.02 (4.33–5.77) 4.81 (3.5–5.49)
Mean QTc interval, ms (range)y 414.3 (381.0–441.0) 415.8 (384.0–447.0)
Demographic evaluations were performed during screening period.
yMeasured at baseline (day 1).
Safety of high-dose formoterol and salbutamol in COPD 6691, hour 0) in plasma potassium concentration. The
mean minimum plasma potassium values were 3.4
and 3.3mmol/l for formoterol and salbutamol,
respectively (P ¼ 0.914). Isolated plasma potas-
sium concentrations o3.2mmol/l were experi-
enced by four patients on formoterol and six
patients on salbutamol (three patients experienced
hypokalaemia during both treatment periods). Of
the 23 recorded values below 3.2mmol/l in the
formoterol treatment group, the lowest was
2.55mmol/l, and of the 22 recorded values in the
salbutamol group, the lowest was 2.39mmol/l.
Overall, the mean AUC for plasma potassium
concentration over the 0–72-h period was compar-
able for formoterol and salbutamol (296.3 and
295.8mmol/l h, respectively; P ¼ 0.390), with no
statistically significant between-treatment differ-
ences in AUC during any interval (0–24 h,
P ¼ 0.729; 24–48 h, P ¼ 0.777; 48–72 h, P ¼ 0.089)
(Fig. 1a).
Formoterol and salbutamol were both associated
with slight, transient increases in blood glucose,
with no relevant between-treatment differences.
The mean maximum blood glucose values were 9.0
and 8.7mmol/l during formoterol and salbutamol
administration, respectively (P ¼ 0.373). Isolated
plasma glucose concentrations above the upper
limit of normal were experienced by all patients,
but increases were slight and transient. The highest
values were 12.77mmol/l with formoterol and
12.38mmol/l with salbutamol. Overall, the mean
AUC for blood glucose concentration over the
0–72-h period was comparable for the two treat-
ments (formoterol, 413.6mmol/l h; salbutamol,
407.3mmol/l h; P ¼ 0.790), with no statistically
significant between-treatment differences in AUC
during any interval (0–24 h, P ¼ 0.208; 24–48 h,
P ¼ 0.736; 48–72 h, P ¼ 0.132) (Fig. 1b).
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Figure 2 Mean (SD) AUC values during 0–72 h time period
and each separate 24-h period for FEV1 in patients with
mild-to-moderate COPD receiving formoterol 24 mg or
salbutamol 600 mg q.i.d.; *Po0.05 vs. salbutamol.
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The mean maximum pulse rate was 88.9 beats/min
in the formoterol group, and 89.9 beats/min in the
salbutamol group. Twelve patients experienced 80
episodes of increased pulse rate to490 beats/min
during the study; 52 instances occurred during
formoterol treatment and 28 during salbutamol
treatment (highest recorded values were 102 and
98 beats/min, respectively).
Both formoterol and salbutamol were associated
with slight increases in mean QTc interval with
mean maximum values of 439ms for both treat-
ments (P ¼ 0.813). A comparison of AUC values
during the 48–72-h period found significantly higher
values for formoterol than salbutamol (9989.4 and
9911.4 ms h, respectively; Po0.01). However, no
significant between-treatment differences in AUC
values were apparent for the 0–24 (P ¼ 0.222),
24–48 (P ¼ 0.147) and 0–72-h (P ¼ 0.162) intervals
(Fig. 1c). One male subject experienced an isolated
occurrence of prolonged QTc interval (461ms) and
one female subject had a borderline QTc value
(460ms) with formoterol. Another female subject
had multiple occurrences of borderline QTc interval
changes during both treatment periods (9 episodes
during salbutamol administration and 13 during
formoterol; including one episode of prolongation,
481ms), although a borderline value of 456ms was
apparent at baseline. The majority of patients,
however, experienced DQTc (Bazett’s) values
o30ms; 95% and 96% of ECG measurements
showing DQTc values o30ms during formoterol
and salbutamol treatment, respectively.
Lung function
Treatment with formoterol and salbutamol was
associated with improvements in lung function, as
shown by increases in FEV1 relative to baseline
values. The mean maximum FEV1 was 2.6 l for both
formoterol and salbutamol (P ¼ 0.624). However, a
between-treatment comparison showed signifi-
cantly greater increases in AUC FEV1 with formo-
terol on all 3 treatment days (mean AUC FEV1
formoterol vs salbutamol on days 1, 2 and 3 were
51.4 l h vs. 47.7 l h, 52.6 l h vs. 46.1 l h, 51.3 l h vs.
48.4 l h, respectively; all Po0.05) (Fig. 2).Discussion and conclusions
While numerous clinical investigations have demon-
strated favourable safety and tolerability of high-
dose formoterol in healthy volunteers8 and patientswith asthma,9–12 relatively few corresponding data
for COPD patients exist in the literature. Current
reports are limited to single-day studies in patients
with acute exacerbations.13,14 However, like those
with asthma, COPD patients may experience
several consecutive days of deteriorating symp-
toms, which introduces the likelihood of high
cumulative doses of a bronchodilator over time.
The present controlled clinical study was designed
to simulate this scenario in COPD patients and to
assess the safety and tolerability of high-dose
formoterol administered over a period of 3 con-
secutive days. To confirm an acceptable safety
margin for formoterol in ‘real-life’ practice, we
studied a dose and schedule (24 mg q.i.d.; total
daily dose of 96 mg) 2–4-times greater than the
current maximum recommended dosage of
12–24 mg b.i.d. (Foradils prescribing information).
This study of patients with COPD confirms the
findings of earlier studies in healthy volunteers and
patients with asthma, in that high-dose formoterol
has a safety and tolerability profile comparable to
that of the short-acting b2-adrenoceptor agonist
salbutamol. Although both agents gave rise to
systemic metabolic effects associated with high-
dose administration of a b2-adrenoceptor agonist
(i.e. decreases in plasma potassium and increases
in blood glucose), no clinically relevant changes
were seen between formoterol and salbutamol.
These findings suggest that formoterol behaves
very much like a short-acting b2-adrenoceptor
agonist in terms of its systemic metabolic safety,
as previously observed in patients with asthma. For
example, Lo¨tvall et al.15 noted that the rapid
normalization of formoterol-induced hypokalaemia
followed the same time-course as with salbutamol.
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course of the systemic effects of high-dose for-
moterol was comparable to that of terbutaline.
A potential consequence of high doses of b2-
adrenoceptor agonists (or any drug that decreases
plasma potassium concentration) is hypokalaemia
and the associated prolongation of the QTc interval,
a known risk factor for cardiac arrhythmia.
Although both high-dose formoterol and salbutamol
were associated with slight increases in the QTc
interval, there were no clinically relevant differ-
ences between the two agents and no other
clinically relevant changes in ECG or blood pressure
were observed. These findings appear to demon-
strate an adequate margin of cardiac safety with
high-dose formoterol taken regularly over 3 days by
COPD patients. The older age of the patients
enrolled in this study (mean 53.8 years; range
45–64 years) may have predisposed the population
to cardiac abnormalities. Nevertheless, caution is
warranted for patients receiving concomitant med-
ications known to prolong the QTc interval (e.g.
quinidine-like drugs) or to reduce plasma potassium
concentrations (e.g. thiazide diuretics or oral
corticosteroids).
The regular use of b2-adrenoceptor agonists in
patients with asthma has recently been associated
with increases in exacerbations, tachyphylaxis and
even mortality.16,17 However, care should be taken
in comparing those data with this study in stable
COPD, as conclusions from studies of short-term,
high-dose formoterol exposure in COPD clearly
cannot be extrapolated to reflect risk of long-term
use in this disease. Studies in patients with asthma
who are administered regularly scheduled treat-
ment with salbutamol suggest that patients who
are homozygous for the Arg polymorphism at codon
16 may respond less well to regular treatment with
b2-adrenoceptor agonists;
18–20 however, this poly-
morphism may be less prevalent in COPD than in
the healthy or asthmatic patient populations 21 and
the effect of genotype on response to b2-adreno-
ceptor agonist treatment in COPD remains to be
investigated.
A possible limitation of the present study was
that extrapulmonary effects were only monitored
up to 3 h post-dose despite the fact that formoterol
has a considerably longer duration of action than
salbutamol. However, the administration of study
drugs at 4-h intervals was chosen to reflect the
likely pattern of patient response to worsening of
symptoms, as might occur during an exacerbation,
and was considered more relevant to real-life
conditions. Despite the potential for cumulative
effects of formoterol, no clinically relevant differ-
ences to salbutamol were apparent in terms ofsystemic effects. Formoterol had a more prolonged
bronchodilatory effect than salbutamol, as shown
by significantly greater values for AUC of FEV1
(Po0.05 for all 3 study days). Taken together, these
findings suggest that high-dose formoterol has a
systemic adverse event profile comparable to high-
dose short-acting b2-adrenoceptor agonists with
greater bronchodilatory effects.
In conclusion, short-term high-dose formoterol
via Aerolizers was well tolerated in patients with
COPD, with a comparable tolerability profile to
high-dose salbutamol. Formoterol has an onset of
action similar to salbutamol in this patient popula-
tion 5,6 and our findings indicate that these patients
could safely tolerate ‘on-demand’ formoterol for
relief of acute symptoms up to a maximum daily
dose of 96 mg for 3 days, in addition to their regular
twice-daily therapy for the treatment of COPD.Acknowledgments
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